Table 3.

Prognostic factors of the progression-free survival.

Prognostic Factor	Univariate Analyses		Multivariate Analyses (Adjusting for Age > 70 Years and ECOG)
	p-Value	HR (95% CI)	p-Value	HR (95% CI)
Country
France (n = 98) vs. Bulgaria (n = 12)	0.6	1.19 (0.62–2.30)
Italy (n = 37) vs. Bulgaria (n = 12)	0.93	1.03 (0.50–2.13)
Age (years)	0.6	0.99 (0.98–1.01)
Age > 70 years (n = 45) vs. ≤70 years (n = 102)	0.83	0.96 (0.64–1.43)	0.12	0.55 (0.26–1.16)
Sex: male (n = 83) vs. female (n = 64)	0.58	1.1 (0.78–1.57)
Arterial hypertension: no (n = 64) vs. yes (n = 51)	0.64	1.1 (0.74–1.64)
Diabetes: no (n = 98) vs. yes (n = 49)	0.74	0.94 (0.65–1.36)
History of myocardial ischemia: no (n = 105) vs. yes (n = 11)	0.83	0.93 (0.48–1.79)
Performance status at the baseline: ECOG 1 (n = 60) vs. ECOG 0 (n = 73)	0.76	1.06 (0.73–1.54)	0.14	0.65 (0.36–1.15)
ECOG 2 (n = 7) vs. ECOG 0 (n = 73)	0.18	1.72 (0.78–3.78)	0.24	0.27 (0.03–2.38)
Abdominal pain: yes (n = 54) vs. no (n = 30)	0.027	1.8 (1.07–3.02)	0.035	2.03 (1.05–3.92)
Tumor location: head (n = 106) vs. tail (n = 7)	0.016	0.38 (0.17–0.84)	0.013	0.23 (0.07–0.73)
Body (n = 34) vs. tail (n = 7)	0.011	0.33 (0.14–0.78)	0.003	0.13 (0.03–0.5)
Tumor size (mm)	0.4	1.01 (0.99–1.02)
Tumor size > 50 mm (n = 16) vs. ≤50 mm (n = 96)	0.21	1.45 (0.81–2.58)
Bilirubin (µmol/L)	0.42	1 (1–1.01)
Albumin (g/L)	0.89	1 (0.98–1.03)
CA19-9 (UI/L)	0.28	1 (1–1)
CA19-9 > 200 UI/L (n = 52) vs. ≤200 UI/L (n = 74)	<0.001	1.79 (1.22–2.63)	0.004	2.3 (1.3–4.08)
Tumor response (RECIST): yes (n = 35) vs. no (n = 110)	0.16	0.74 (0.48–1.12)
Secondary surgery: yes (n = 24) vs. no (n = 123)	0.011	0.52 (0.32–0.86)	0.007	0.37 (0.18–0.76)
Chemotherapy regimen: FFX (n = 87) vs. GN (n = 60)	0.80	1.05 (0.73–1.51)	0.5	1.24 (0.66–2.32)

Notes: CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; FFX: FOLFIRINOX; GN: gemcitabine/nab-paclitaxel; HR: hazard ratio; RECIST: response evaluation criteria in solid tumors.